Company CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:49:29 2024-04-24 pm EDT			5-day change	1st Jan Change
0.2048 ^USD	-2.48%		+0.20%	-83.87%

Apr. 23	Transcript : CNS Pharmaceuticals, Inc. - Special Call
Apr. 01	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Number of employees: 4

Managers	Title	Age	Since
John Climaco CEO	Chief Executive Officer	55	17-08-31
Christopher Downs DFI	Director of Finance/CFO	45	19-11-12
Sandra Silberman CTO	Chief Tech/Sci/R&D Officer	69	17-11-30
Donald Picker CTO	Chief Tech/Sci/R&D Officer	78	17-12-31

Members of the board	Title	Age	Since
Donald Picker CTO	Chief Tech/Sci/R&D Officer	78	17-12-31
John Climaco CEO	Chief Executive Officer	55	17-08-31
Faith Charles CHM	Chairman	62	23-01-02
Jeffry Keyes BRD	Director/Board Member	51	18-06-24
Bettina Cockroft BRD	Director/Board Member	57	23-05-07
Jerzy Gumulka BRD	Director/Board Member	75	17-11-07
Carl Evans BRD	Director/Board Member	77	18-07-08
Amy Mahery BRD	Director/Board Member	-	Jan. 17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,634,932	10,165,242 ( 95.58 %)	0	95.58 %

Name	Equities	%	Valuation
John Climaco 2.558 %	215,676	2.558 %	78 075 $
Armistice Capital LLC 1.447 %	122,000	1.447 %	44 164 $
Christopher Downs 1.227 %	103,438	1.227 %	37 445 $
Vanguard Group, Inc. (Subfiler) 0.6924 %	58,369	0.6924 %	21 130 $
Smith Anglin Financial LLC 0.5931 %	50,000	0.5931 %	18 100 $
Jerzy Gumulka 0.5101 %	43,006	0.5101 %	15 568 $
Carl Evans 0.3969 %	33,458	0.3969 %	12 112 $
Geode Capital Management LLC 0.2899 %	24,436	0.2899 %	8 846 $
STATE STREET CORPORATION 0.2676 %	22,556	0.2676 %	8 165 $
FSM Wealth Advisors LLC 0.2264 %	19,084	0.2264 %	6 908 $

CNS Pharmaceuticals, Inc.

2100 West Loop South Suite 900

77027, Houston

http://www.cnspharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CNS PHARMACEUTICALS, INC.	-83.87%	2.23M
IQVIA HOLDINGS INC.	+3.29%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+7.88%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.15%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.42%	18.47B
MEDPACE HOLDINGS, INC.	+29.14%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.16%	12.33B
UNITED THERAPEUTICS CORPORATION	+8.56%	11.03B

Other Biotechnology & Medical Research